title: Response to "Ipilimumab (Yervoy) and the TGN1412 catastrophe".
authors.forename: Michael A
authors.initials: MA
authors.lastname: Curran
authors.forename: Margaret K
authors.initials: MK
authors.lastname: Callahan
authors.forename: Sumit K
authors.initials: SK
authors.lastname: Subudhi
authors.forename: James P
authors.initials: JP
authors.lastname: Allison
mesh_terms: D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D060908:CTLA-4 Antigen / Q000037:antagonists & inhibitors*; D006801:Humans; D007116:Immunization, Passive / Q000379:methods*; D000074324:Ipilimumab; D008545:Melanoma / Q000628:therapy*; D012878:Skin Neoplasms / Q000628:therapy*
chemical_list: D000911:Antibodies, Monoclonal; D060908:CTLA-4 Antigen; D000074324:Ipilimumab